NO315118B1 - 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasöytiske sammensetninger inneholdende slike - Google Patents

1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasöytiske sammensetninger inneholdende slike Download PDF

Info

Publication number: NO315118B1
Authority: NO; Norway
Prior art keywords: group; alkyl; phenyl; pyrido; compound according
Prior art date: 1997-07-29

Application number

NO20000394A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000394L (no

NO20000394D0 (no

Inventor

Ferrer Jordi Gracia

Maria Isabel Crespo Crespo

Noverola Armando Vega

Garcia Andres Fernandez

Original Assignee

Almirall Prodesfarma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-29

Filing date

2000-01-26

Publication date

2003-07-14

2000-01-26 Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa

2000-01-26 Publication of NO20000394D0 publication Critical patent/NO20000394D0/no

2000-03-27 Publication of NO20000394L publication Critical patent/NO20000394L/no

2003-07-14 Publication of NO315118B1 publication Critical patent/NO315118B1/no

Links

239000008194 pharmaceutical composition Substances 0.000 title description 4
DIAJZQVKZBSZCG-UHFFFAOYSA-N C1=CN=C2C=NN3C=NN=C3C2=C1 Chemical class C1=CN=C2C=NN3C=NN=C3C2=C1 DIAJZQVKZBSZCG-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 15
-1 methylenedioxy- Chemical class 0.000 claims description 11
125000005843 halogen group Chemical group 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 5
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 5
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
208000025865 Ulcer Diseases 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
231100000397 ulcer Toxicity 0.000 claims description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
FZOKILRFZOVKRQ-UHFFFAOYSA-N N=1N2C(CC(C)C)=NN=C2C2=CC=CN=C2C=1C1=CC=C(F)C=C1 Chemical compound N=1N2C(CC(C)C)=NN=C2C2=CC=CN=C2C=1C1=CC=C(F)C=C1 FZOKILRFZOVKRQ-UHFFFAOYSA-N 0.000 claims description 2
YMNVGDHORTVWCT-UHFFFAOYSA-N [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C3=NN=C(CC4CC4)N3N=2)=C1 Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C3=NN=C(CC4CC4)N3N=2)=C1 YMNVGDHORTVWCT-UHFFFAOYSA-N 0.000 claims description 2
CNINWDBQCDAKFK-UHFFFAOYSA-N [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C3=NN=C(CC4CCC4)N3N=2)=C1 Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=NC=CC=C3C3=NN=C(CC4CCC4)N3N=2)=C1 CNINWDBQCDAKFK-UHFFFAOYSA-N 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
208000026278 immune system disease Diseases 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
125000000753 cycloalkyl group Chemical group 0.000 claims 2
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 2
125000004076 pyridyl group Chemical group 0.000 claims 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical group C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
XCJPTECQPSWMRE-UHFFFAOYSA-N 5-cyclopropyl-8-phenyl-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,10,12-hexaene Chemical compound C1CC1C1=NN=C2N1N=C(C=1C=CC=CC=1)C1=NC=CC=C12 XCJPTECQPSWMRE-UHFFFAOYSA-N 0.000 claims 1
206010020751 Hypersensitivity Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000026935 allergic disease Diseases 0.000 claims 1
208000030961 allergic reaction Diseases 0.000 claims 1
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
238000007363 ring formation reaction Methods 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000000725 suspension Substances 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
150000002391 heterocyclic compounds Chemical class 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000000243 solution Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000001914 filtration Methods 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
239000011574 phosphorus Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
101710111837 Cyclic phosphodiesterase Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
150000002429 hydrazines Chemical class 0.000 description 3
150000007857 hydrazones Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
238000009835 boiling Methods 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000009109 curative therapy Methods 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
230000006378 damage Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
JVANLUCASVHWEW-UHFFFAOYSA-N pyridazine Chemical compound N1=C=C=C=C=N1 JVANLUCASVHWEW-UHFFFAOYSA-N 0.000 description 2
WCKGRSPYFFVKQT-UHFFFAOYSA-N pyridazine;dihydrochloride Chemical compound Cl.Cl.C1=CC=NN=C1 WCKGRSPYFFVKQT-UHFFFAOYSA-N 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
CUADCEFWXFDKEK-UHFFFAOYSA-N 2-benzoylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1C(=O)C1=CC=CC=C1 CUADCEFWXFDKEK-UHFFFAOYSA-N 0.000 description 1
RFONJRMUUALMBA-UHFFFAOYSA-N 2-methanidylpropane Chemical compound CC(C)[CH2-] RFONJRMUUALMBA-UHFFFAOYSA-N 0.000 description 1
SGTXILTYXULEQD-UHFFFAOYSA-N 2H-triazolo[4,5-f]phthalazine Chemical class N1=NC=C2C3=NNN=C3C=CC2=C1 SGTXILTYXULEQD-UHFFFAOYSA-N 0.000 description 1
PNRSQGPMSVOCOE-UHFFFAOYSA-N 3-(2-methylpropyl)-6-phenyl-[1,2,4]triazolo[3,4-a]phthalazine Chemical compound N=1N2C(CC(C)C)=NN=C2C2=CC=CC=C2C=1C1=CC=CC=C1 PNRSQGPMSVOCOE-UHFFFAOYSA-N 0.000 description 1
UYKXYJVJFRLVIF-UHFFFAOYSA-N 5-chloro-8-phenylpyrido[2,3-d]pyridazine Chemical compound C12=NC=CC=C2C(Cl)=NN=C1C1=CC=CC=C1 UYKXYJVJFRLVIF-UHFFFAOYSA-N 0.000 description 1
LQGNAZVVIMUYDQ-UHFFFAOYSA-N 5-tert-butyl-8-phenyl-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7,10,12-hexaene Chemical compound N=1N2C(C(C)(C)C)=NN=C2C2=CC=CN=C2C=1C1=CC=CC=C1 LQGNAZVVIMUYDQ-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
206010017943 Gastrointestinal conditions Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
KFRAKQXWWCKHKF-UHFFFAOYSA-N azanium;dichloromethane;ethanol;hydroxide Chemical compound [NH4+].[OH-].CCO.ClCCl KFRAKQXWWCKHKF-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
230000008455 cerebrovascular function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000000095 emetic effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000001477 organic nitrogen group Chemical group 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
GIVUQTUKKWDKHE-UHFFFAOYSA-N pyrido[2,3-d]pyridazine Chemical compound C1=NN=CC2=CC=CN=C21 GIVUQTUKKWDKHE-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Immunology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

NO20000394A 1997-07-29 2000-01-26 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasöytiske sammensetninger inneholdende slike NO315118B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES009701670A ES2137113B1 (es)	1997-07-29	1997-07-29	Nuevos derivados de triazolo-piridazinas heterociclicos.
PCT/EP1998/004340 WO1999006404A1 (fr)	1997-07-29	1998-07-13	Derives de 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine et compositions pharmaceutiques a base de ces derives

Publications (3)

Publication Number	Publication Date
NO20000394D0 NO20000394D0 (no)	2000-01-26
NO20000394L NO20000394L (no)	2000-03-27
NO315118B1 true NO315118B1 (no)	2003-07-14

Family

ID=8300216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000394A NO315118B1 (no)	1997-07-29	2000-01-26	1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasöytiske sammensetninger inneholdende slike

Country Status (36)

Country	Link
US (2)	US6407108B1 (fr)
EP (1)	EP1001955B1 (fr)
JP (1)	JP4320118B2 (fr)
KR (1)	KR20010022353A (fr)
CN (1)	CN1135231C (fr)
AR (1)	AR015927A1 (fr)
AT (1)	ATE207069T1 (fr)
AU (1)	AU737709B2 (fr)
BG (1)	BG64448B1 (fr)
BR (1)	BR9810829B1 (fr)
CA (1)	CA2298935A1 (fr)
CO (1)	CO4970780A1 (fr)
CZ (1)	CZ290208B6 (fr)
DE (1)	DE69802100T2 (fr)
DK (1)	DK1001955T3 (fr)
EE (1)	EE04313B1 (fr)
EG (1)	EG24041A (fr)
ES (2)	ES2137113B1 (fr)
HK (1)	HK1024914A1 (fr)
HU (1)	HUP0004708A3 (fr)
ID (1)	ID24506A (fr)
IL (1)	IL134081A (fr)
MY (1)	MY118796A (fr)
NO (1)	NO315118B1 (fr)
NZ (1)	NZ502356A (fr)
PE (1)	PE111099A1 (fr)
PL (1)	PL191031B1 (fr)
PT (1)	PT1001955E (fr)
RU (1)	RU2202552C2 (fr)
SI (1)	SI1001955T1 (fr)
SK (1)	SK284046B6 (fr)
TR (1)	TR200000243T2 (fr)
TW (1)	TW542837B (fr)
UA (1)	UA60339C2 (fr)
WO (1)	WO1999006404A1 (fr)
ZA (1)	ZA986248B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2792938B1 (fr)	1999-04-28	2001-07-06	Warner Lambert Co	NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
JP5038568B2 (ja)	1999-08-21	2012-10-03	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	協力剤の組合せ物
WO2002080974A1 (fr) *	2001-04-04	2002-10-17	Sankyo Company, Limited	Utilisation medicale d'inhibiteur de production de cytokine
PT1429807E (pt)	2001-09-19	2007-05-31	Altana Pharma Ag	Combinação de um nsaid e de um inibidor de pde-4
FR2832711B1 (fr) *	2001-11-26	2004-01-30	Warner Lambert Co	Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
ATE524471T1 (de) *	2002-11-06	2011-09-15	Aska Pharm Co Ltd	Pyrazolonaphthyridinderivat
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
RU2246496C1 (ru) *	2003-09-12	2005-02-20	Тец Виктор Вениаминович	Вещество с противовирусной и антибактериальной активностью на основе производных 2,8-дитиоксо-1h-пирано[2,3-d, 6,5-d`] дипиримидина и их 10-аза-аналогов
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
US8008317B2 (en) *	2005-06-10	2011-08-30	Merck Sharp & Dohme Corp.	Inhibitors of akt activtiy
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP1928437A2 (fr)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenese par modulation du recepteur muscarinique
AU2006289838B2 (en) *	2005-09-15	2011-08-18	Aska Pharmaceutical Co., Ltd.	Heterocyclic compound, and production process and use thereof
CA2625153A1 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134077A2 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenèse induite par le récepteur 5ht
EP2382975A3 (fr)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogénèse par modulation d'angiotensine
WO2008021781A1 (fr)	2006-08-07	2008-02-21	Incyte Corporation	Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
MX2009002496A (es)	2006-09-08	2009-07-10	Braincells Inc	Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
AU2007323725B2 (en)	2006-11-22	2014-02-20	Incyte Holdings Corporation	Imidazotriazines and imidazopyrimidines as kinase inhibitors
EP2231669A1 (fr) *	2008-01-09	2010-09-29	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Inhibiteurs de phosphodiestérase
HUE034716T2 (hu)	2008-05-21	2018-02-28	Incyte Holdings Corp	2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására
EP2196465A1 (fr)	2008-12-15	2010-06-16	Almirall, S.A.	Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (fr)	2009-02-27	2010-09-08	Almirall, S.A.	Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
AU2010338038B2 (en)	2009-12-31	2015-07-09	Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Tricyclic compounds for use as kinase inhibitors
CN102812027B (zh)	2010-02-03	2015-01-07	因西特公司	作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪
EP2380890A1 (fr)	2010-04-23	2011-10-26	Almirall, S.A.	Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2394998A1 (fr)	2010-05-31	2011-12-14	Almirall, S.A.	Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
WO2012098387A1 (fr)	2011-01-18	2012-07-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
WO2013005057A1 (fr)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Nouveaux composés
WO2013005041A1 (fr)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Composés hétérocycliques tricycliques en tant qu'inhibiteurs de kinases
WO2013004984A1 (fr)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncologicas (Cnio)	Composés tricycliques pour l'utilisation en tant qu'inhibiteurs de kinase
EP2804603A1 (fr)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3122670A1 (de)	1981-06-06	1982-12-23	Dr. Karl Thomae Gmbh, 7950 Biberach	"neue 1,4,9,10-tetrahydro-pyrazolo(4,3-e) pyrido(3,2-b)(1,4)diazepin-10-one, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen"
FI81350C (fi) *	1982-01-18	1990-10-10	Lepetit Spa	Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
AU7238191A (en) *	1990-02-19	1991-09-03	Chugai Seiyaku Kabushiki Kaisha	Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom
TW365606B (en) *	1991-10-09	1999-08-01	Syntex Inc	Pyrido pyridazinone and pyridazinthione compounds
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds

1997
- 1997-07-29 ES ES009701670A patent/ES2137113B1/es not_active Expired - Lifetime
1998
- 1998-07-13 WO PCT/EP1998/004340 patent/WO1999006404A1/fr not_active Application Discontinuation
- 1998-07-13 PT PT78400158T patent/PT1001955E/pt unknown
- 1998-07-13 CA CA002298935A patent/CA2298935A1/fr not_active Abandoned
- 1998-07-13 PL PL338214A patent/PL191031B1/pl not_active IP Right Cessation
- 1998-07-13 IL IL13408198A patent/IL134081A/en active IP Right Grant
- 1998-07-13 EP EP98940218A patent/EP1001955B1/fr not_active Expired - Lifetime
- 1998-07-13 HU HU0004708A patent/HUP0004708A3/hu unknown
- 1998-07-13 BR BRPI9810829-8A patent/BR9810829B1/pt not_active IP Right Cessation
- 1998-07-13 SI SI9830042T patent/SI1001955T1/xx unknown
- 1998-07-13 CZ CZ2000333A patent/CZ290208B6/cs not_active IP Right Cessation
- 1998-07-13 TR TR2000/00243T patent/TR200000243T2/xx unknown
- 1998-07-13 UA UA2000010486A patent/UA60339C2/uk unknown
- 1998-07-13 AU AU88612/98A patent/AU737709B2/en not_active Ceased
- 1998-07-13 DE DE69802100T patent/DE69802100T2/de not_active Expired - Fee Related
- 1998-07-13 KR KR1020007000932A patent/KR20010022353A/ko not_active Application Discontinuation
- 1998-07-13 DK DK98940218T patent/DK1001955T3/da active
- 1998-07-13 SK SK86-2000A patent/SK284046B6/sk not_active IP Right Cessation
- 1998-07-13 AT AT98940218T patent/ATE207069T1/de not_active IP Right Cessation
- 1998-07-13 RU RU2000104863/04A patent/RU2202552C2/ru not_active IP Right Cessation
- 1998-07-13 EE EEP200000052A patent/EE04313B1/xx not_active IP Right Cessation
- 1998-07-13 ID IDW20000180A patent/ID24506A/id unknown
- 1998-07-13 JP JP2000505162A patent/JP4320118B2/ja not_active Expired - Fee Related
- 1998-07-13 CN CNB988081210A patent/CN1135231C/zh not_active Expired - Fee Related
- 1998-07-13 NZ NZ502356A patent/NZ502356A/xx unknown
- 1998-07-13 ES ES98940218T patent/ES2162466T3/es not_active Expired - Lifetime
- 1998-07-14 ZA ZA986248A patent/ZA986248B/xx unknown
- 1998-07-16 TW TW087111560A patent/TW542837B/zh not_active IP Right Cessation
- 1998-07-27 MY MYPI98003421A patent/MY118796A/en unknown
- 1998-07-28 CO CO98042905A patent/CO4970780A1/es unknown
- 1998-07-29 EG EG88998A patent/EG24041A/xx active
- 1998-07-29 AR ARP980103719A patent/AR015927A1/es active IP Right Grant
- 1998-07-30 PE PE1998000682A patent/PE111099A1/es not_active Application Discontinuation
2000
- 2000-01-26 NO NO20000394A patent/NO315118B1/no not_active IP Right Cessation
- 2000-01-27 BG BG104112A patent/BG64448B1/bg unknown
- 2000-01-28 US US09/496,019 patent/US6407108B1/en not_active Expired - Fee Related
- 2000-06-15 HK HK00103595A patent/HK1024914A1/xx not_active IP Right Cessation
2002
- 2002-01-08 US US10/038,777 patent/US20020183326A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20000394L (no)	2000-03-27
CZ290208B6 (cs)	2002-06-12
BG64448B1 (en)	2005-02-28
EG24041A (en)	2008-04-03
TR200000243T2 (tr)	2000-07-21
SK862000A3 (en)	2000-07-11
IL134081A (en)	2004-02-08
AR015927A1 (es)	2001-05-30
ID24506A (id)	2000-07-20
NZ502356A (en)	2001-03-30
US20020183326A1 (en)	2002-12-05
JP4320118B2 (ja)	2009-08-26
RU2202552C2 (ru)	2003-04-20
NO20000394D0 (no)	2000-01-26
MY118796A (en)	2005-01-31
PE111099A1 (es)	1999-11-18
DE69802100D1 (de)	2001-11-22
DE69802100T2 (de)	2002-03-14
PL191031B1 (pl)	2006-03-31
CN1266434A (zh)	2000-09-13
SI1001955T1 (en)	2002-02-28
PT1001955E (pt)	2002-02-28
JP2001512121A (ja)	2001-08-21
WO1999006404A1 (fr)	1999-02-11
PL338214A1 (en)	2000-10-09
DK1001955T3 (da)	2001-11-19
US6407108B1 (en)	2002-06-18
ES2137113A1 (es)	1999-12-01
ATE207069T1 (de)	2001-11-15
CA2298935A1 (fr)	1999-02-11
HK1024914A1 (en)	2000-10-27
CN1135231C (zh)	2004-01-21
KR20010022353A (ko)	2001-03-15
EP1001955A1 (fr)	2000-05-24
CO4970780A1 (es)	2000-11-07
EP1001955B1 (fr)	2001-10-17
TW542837B (en)	2003-07-21
UA60339C2 (uk)	2003-10-15
HUP0004708A2 (hu)	2001-07-30
ES2162466T3 (es)	2001-12-16
SK284046B6 (sk)	2004-08-03
CZ2000333A3 (cs)	2000-05-17
ZA986248B (en)	1999-02-05
BG104112A (en)	2001-01-31
IL134081A0 (en)	2001-04-30
BR9810829B1 (pt)	2009-08-11
ES2137113B1 (es)	2000-09-16
EE04313B1 (et)	2004-06-15
HUP0004708A3 (en)	2002-11-28
EE200000052A (et)	2000-10-16
BR9810829A (pt)	2000-07-25
AU8861298A (en)	1999-02-22
AU737709B2 (en)	2001-08-30

Legal Events

Date	Code	Title	Description
2010-03-01	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO315118B1 (no)	2003-07-14	1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazinderivater samt farmasöytiske sammensetninger inneholdende slike
CA2557541C (fr)	2014-12-16	Derives de pyrimidine
TW378210B (en)	2000-01-01	Tetracyclic derivatives; process of preparation and use
TW406082B (en)	2000-09-21	Pyridazino quinoline compounds
MX2008001020A (es)	2008-03-25	Un monohidrato de pirrolo[1-2-b]pirazol piridin quinolin substituido como inhibidor de factor de crecimiento de transformacion-beta (tgf-beta).
JP2008523070A (ja)	2008-07-03	バニロイド受容体サブタイプ１（ｖｒ１）に対する拮抗薬およびこの使用
CA2847075A1 (fr)	2013-03-07	Pyrimidines annelees substituees et leur utilisation
AU4564500A (en)	2000-12-05	4,5,6,7-tetrahydroindazole derivatives as antitumor agents
CA2934553A1 (fr)	2015-06-25	Derives de benzodiazepine, compositions et procedes de traitement de la deficience cognitive
CN106456653A (zh)	2017-02-22	高胰岛素血症相关病症的治疗
JPH0412269B2 (fr)	1992-03-04
CA2816639A1 (fr)	2012-05-10	Carbamates substitues par des benzyles et leur utilisation
AU2002360618A1 (en)	2003-07-09	Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
WO2014043246A1 (fr)	2014-03-20	Inhibiteurs d'énoyle réductase ayant une activité antibactérienne
MX2007006172A (es)	2007-07-13	Nuevos derivados de piridotienopirimidina.
IL126206A (en)	2001-06-14	History 2 - (3H) - Oxazolone and their use as COX-2 enzyme inhibitors, processes for their preparation and pharmaceutical preparations containing them
WO1995007893A1 (fr)	1995-03-23	Derives heteroaromatiques tricycliques fusionnes en tant que ligands pour les sous-types de recepteurs dopaminergiques
NO136251B (fr)	1977-05-02
TW201120048A (en)	2011-06-16	Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
JP2009502832A (ja)	2009-01-29	新規ピリド［３’，２’：４，５］フロ［３，２−ｄ］ピリミジン誘導体
CN116283993B (zh)	2024-05-03	一种嘧啶类化合物及其制备方法和应用
MXPA00000910A (en)	2002-03-05	1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
BRPI0903803B1 (pt)	2019-07-09	Composto, processo de preparação, composição farmacêutica e uso dos compostos
TWI325322B (en)	2010-06-01	Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one; and 7-pyrimidiny-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1h)one derivatives
WO2021038452A1 (fr)	2021-03-04	Nouveaux agents thérapeutiques pour le traitement de pathologies hématologiques